CMB Stock Overview
A clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Cambium Bio Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.40 |
| 52 Week High | AU$1.60 |
| 52 Week Low | AU$0.40 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -20.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -66.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | 1.4% |
| 1Y | n/a | 18.6% | 15.5% |
Return vs Industry: Insufficient data to determine how CMB performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how CMB performed against the Australian Market.
Price Volatility
| CMB volatility | |
|---|---|
| CMB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: CMB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CMB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Karolis Rosickas | www.cambium.bio |
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. Its lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus for wound healing indications.
Cambium Bio Limited Fundamentals Summary
| CMB fundamental statistics | |
|---|---|
| Market cap | AU$3.94m |
| Earnings (TTM) | AU$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMB income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$0 |
| Other Expenses | AU$0 |
| Earnings | AU$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CMB perform over the long term?
See historical performance and comparison